Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 6/2003

01-05-2003 | Leading Article

Dietary Lipids in the Aetiology of Alzheimer’s Disease

Implications for Therapy

Author: Dr Janelle L. Cooper

Published in: Drugs & Aging | Issue 6/2003

Login to get access

Abstract

Amyloid plaques and neurofibrillary tangles are the neuropathological hallmarks of Alzheimer’s disease (AD), but no conclusive evidence has emerged showing that these hallmarks are the cause and not a product of the disease. Many studies have implicated oxidation and inflammation in the AD process, and there is growing evidence that abnormalities of lipid metabolism also play a role. Using epidemiology to elucidate risk factors and histological changes to suggest possible mechanisms, the hypothesis is advanced that dietary lipids are the principal risk factor for the development of late-onset sporadic AD.
The degree of saturation of fatty acids and the position of the first double bond in essential fatty acids are the most critical factors determining the effect of dietary fats on the risk of AD, with unsaturated fats and n-3 double bonds conferring protection and an overabundance of saturated fats or n-6 double bonds increasing the risk. The interaction of dietary lipids and apolipoprotein E isoforms may determine the risk and rate of sustained autoperoxidation within cellular membranes and the efficacy of membrane repair.
Interventions involving dietary lipids and lipid metabolism show great promise in slowing or possibly averting the development of AD, including dietary changes, cholesterol-modifying agents and antioxidants.
Literature
1.
Alzheimer A. Uber eigenartige Krankheitsfalle des spateren Alters. Zbl Ges Neurol Psychiat 1911; 4: 356–85CrossRef
2.
3.
Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer’s disease (CERAD): II. Standardization of the neuropathological assessment of Alzheimer’s disease. Neurology 1991; 41: 479–86PubMedCrossRef
4.
Selkoe D. Toward a comprehensive theory for Alzheimer’s disease. Ann N Y Acad Sci 2000; 924: 17–25PubMedCrossRef
5.
Joseph J, Shukitt-Hale B, Denisova NA, et al. Copernicus revisited: amyloid beta in Alzheimer’s disease. 2001 Jan–Feb; 22(1): 131–46
6.
Pratico D, Uryu K, Leight S, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001 Jun; 21(12): 4183–7PubMed
7.
Snowdon DA. Aging and Alzheimer’s disease: lessons from the Nun study. Gerontologist 1997; 37(2): 150–6PubMedCrossRef
8.
Masliah E, Mallory M, Hansen L, et al. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 1993 Jan; 43(1): 192–7PubMedCrossRef
9.
National Institute on Aging and Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer’s disease. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiol Aging 1997; 18(4 Suppl.): S1–3
10.
Harman D. Free radical theory of aging: Alzheimer’s disease pathogenesis. Aging 1995; 18: 97–119
11.
Markesbery WR. The role of oxidative stress in Alzheimer disease. Arch Neurol 1999 Dec, 52
12.
Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71Suppl. 2: 621S–9SPubMed
13.
Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 2001 Jun; 8(7): 721–38PubMedCrossRef
14.
Neuroinflammation Working Group. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21: 383–421CrossRef
15.
Floyd R. Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic Biol Med 1999, 55
16.
Lue LF, Brachova WH, Civin WH, et al. Inflammation, Abeta deposition, and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration. J Neuropathol Exp Neurol 1996; 55: 1083–8PubMed
17.
Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci 1994 Dec; 17(12): 525–30PubMedCrossRef
18.
Poirier J. Apolipoprotein E and Alzheimer’s disease: a role in amyloid catabolism. Ann N Y Acad Sci 2000; 924: 81–90PubMedCrossRef
19.
Farooqui AA, Horrocks LA. Lipid peroxides in the free radical pathophysiology of brain diseases. Cell Mol Neurobiol 1998: 18(6): 599–608PubMedCrossRef
20.
Roher AE, Kuo YM, Kokjohn KM, et al. Amyloid and lipids in the pathology of Alzheimer’s disease. Int J Exp Clin Invest 1999; 6: 136–45
21.
22.
Tanzi RE, Kovacs DM, Kim TW, et al. The gene defects responsible for familial Alzheimer’s disease. Neurobiol Dis 1996; 3(3): 159–68PubMedCrossRef
23.
Jarvik G, Larson EB, Goddard K, et al. Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Am J Hum Genet 1996 Jan; 58(1): 191–200PubMed
24.
Chandra V, Pandav R. Gene-environment interaction in Alzheimer’s disease: a potential role for cholesterol. Neuroepidemiology 1998; 17(5): 225–32PubMedCrossRef
25.
Munoz DG, Feldman H. Causes of Alzheimer’s disease. CMAJ 2000 Jan 11; 162(1): 65–72PubMed
26.
Ogunniyi A, Osuntokun B. Relatively low prevalence of Alzheimer’s disease in developing countries and the racial factor in dementia research. Ethn Dis 1991 Fall; 1(4): 394–5PubMed
27.
Osuntokun BO, Ogunniyi AO, Lekwauwa UG. Alzheimer’s disease in Nigeria. Afr J Med Med Sci 1992 Dec; 21(2): 71–7PubMed
28.
Hendrie HC, Osuntokun BO, Hall KS, et al. Prevalence of Alzheimer’s disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry 1995 Oct; 152(10): 1485–92PubMed
29.
Hendrie HC, Baiyewu O, Eidemire D, et al. Cross-cultural perspectives: Caribbean, Native American, and Yoruba. Int Psychogeriatr 1996; 8Suppl. 3: 483–6PubMed
30.
Chandra V, Pandav R, Dodge HH, et al. Incidence of Alzheimer’s disease in a rural community in India. Neurology 2001 Sep 25; 57: 985–9PubMedCrossRef
31.
White L, Petrovitch H, Ross GW, et al. Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. JAMA 1996 Sep 25; 276(12): 955–60PubMedCrossRef
32.
Shadlen MF, Larson EB, Yukawa M. The epidemiology of Alzheimer’s disease and vascular dementia in Japanese and African-American populations: the search for etiological clues. Neurobiol Aging 2000 Mar–Apr; 21(2): 171–81PubMedCrossRef
33.
Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoproprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261: 921–3PubMedCrossRef
34.
Osuntokun BO, Sahota A, Ogunniyi AO, et al. Lack of association between apolipoprotein E epsilon 4 and Alzheimer’s disease in elderly Nigerians. Ann Neurol 1995 Sep; 38(3): 463–5PubMedCrossRef
35.
Ogunniyi A, Baiyewu O, Gureje O, et al. Epidemiology of dementia in Nigeria: results from the Indianapolis-Ibadan study. Eur J Neurol 2000 Sep; 7(5): 485–90PubMedCrossRef
36.
Havlik RJ, Izmirlian G, Petrovitch H, et al. APOE-epsilon4 predicts incident AD in Japanese-American men: the Honolulu-Asia aging study. Neurology 2000 Apr 11; 54(7): 1526–9PubMedCrossRef
37.
Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in 2 communities. JAMA 2001 Feb 14; 285(6): 739–47PubMedCrossRef
38.
Hendrie HC. Cross cultural studies of dementia [abstract 975]. 7th International Conference on Alzheimer’s Disease and Related Disorders; 2000 Jul 9–18; Washington, DC. Neurobiol Aging 2000 May–Jun; 21(1S): S214CrossRef
39.
Grant WB. Dietary links to Alzheimer’s disease. Alz Dis Rev 1997; 2: 42–55
40.
Grant WB. Dietary links to Alzheimer’s disease: 1999 update. J Alzheimers Dis 1999; 1: 197–201PubMed
41.
Grant WB, Campbell A, Itzhaki RF, et al. The significance of environmental factors in the etiology of Alzheimers disease. J Alzheimers Dis 2002; 4(3): 179–89PubMed
42.
Smith MA, Petot GJ, Perry G. Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer’s disease [commentary]. Alz Dis Rev 1997; 2: 58–60
43.
Smith MA, Petot GJ, Perry G. Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer’s disease. J Alzheimers Dis 1999; 1: 203–6PubMed
44.
Petot GJ, Cook TB, Chen CH, et al. A high fat diet during adulthood increases risk for Alzheimer’s disease for those with the APOE-e4 allele. [poster 1124]. 7th International Conference on Alzheimer’s Disease and Related Disorders; 2000 Jul 9–18; Washington, DC. Neurobiol Aging 2000 May–Jun; 21(1S): S246CrossRef
45.
Strohmeyer R, Rogers J. Molecular and cellular mediators of Alzheimer’s disease inflammation. J Alzheimers Dis 2001 Feb; 3(1): 131–57PubMed
46.
Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002 Aug; 52(2): 168–74PubMedCrossRef
47.
Kuehl Jr FA, Egan RW. Prostaglandins, arachidonic acid, and inflammation. Science 1980 Nov 28; 210(4473): 978–84PubMedCrossRef
48.
Samuelsson B. Arachidonic acid metabolism: role in inflammation. Z Rheumatol 1991; 50Suppl. 1: 3–6PubMed
49.
Simopoulos AP. Summary of the NATO advanced research workshop on dietary omega 3 and omega 6 fatty acids: biological effects and nutritional essentiality. J Nutr 1989 Apr; 119(4): 521–8PubMed
50.
Agranoff BW, Benjamins JA, Hajra AK. Lipids. In: Siegel GJ, editor. Basic neurochemistry: molecular, cellular and medical aspects. 6th ed. Philadelphia: Lippincott-Raven, 1999
51.
Sperling RI. The effects of dietary n-3 polyunsaturated fatty acids on neutrophils. Proc Nutr Soc 1998 Nov; 57(4): 527–34PubMedCrossRef
52.
Murray RK, Granne D, Mayes PA. Lipids of physiologic significance. In: Murray RK, et al. Harper’s biochemistry. 25th ed. Stamford (CT): McGraw-Hill, 1999: 169–70
53.
Choe MK, Jackson C, Yu BP. Lipid peroxidation contributes to age-related membrane rigidity. Free Radic Biol Med 1995; 18: 977–84PubMedCrossRef
54.
Racchi M, Daglia M, Lanni C, et al. Antiradical activity of water soluble components in common diet vegetables. J Agric Food Chem 2002 Feb 27; 50(5): 1272–7PubMedCrossRef
55.
Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002 Jun 26; 287(24): 3223–9PubMedCrossRef
56.
O’Reilly JD, Sanders TA, Wiseman H. Flavonoids protect against oxidative damage to LDL in vitro: use in selection of a flavonoid rich diet and relevance to LDL oxidation resistance ex vivo? Free Radic Res 2000 Oct; 33(4): 419–26PubMedCrossRef
57.
Blaauwwiekel EE, Beusekamp BJ, Sluiter WJ, et al. Apolipoprotein E genotype is a determinant of low-density lipoprotein cholesterol and of its response to a low-cholesterol diet in type 1 diabetic patients with elevated urinary albumin excretion. Diabet Med 1998 Dec; 15(12): 1031–5PubMedCrossRef
58.
Isbir T, Agachan B, Yilmaz H, et al. Apolipoprotein-E gene polymorphism and lipid profiles in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2001 Mar–Apr; 16(2): 77–81PubMedCrossRef
59.
Guz G, Nurhan Ozdemir F, Sezer S, et al. Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis 2000 Oct; 36(4): 826–36PubMedCrossRef
60.
Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002 Mar; 59(3): 378–84PubMedCrossRef
61.
Kuo YM, Emmerling MR, Bisgaier CL, et al. Elevated low-density lipoprotein in Alzheimer’s disease correlates with brain abeta 1–42 levels. Biochem Biophys Res Commun 1998: 252: 711–5PubMedCrossRef
62.
Kemin Q, Hall M, Deckelbaum RJ. Long-chain polyunsaturated fatty acid accretion in brain. Curr Opin Clin Nutr Metab Care 2002; 5: 133–8CrossRef
63.
Angulo-Guerrero O, Oliart RR. Effects of dietary polyunsaturated fatty acids on rat brain plasma membrane fatty acid composition. Arch Latinoam Nutr 1998 Dec; 48(4): 287–92PubMed
64.
Fernstrom JD. Effects of dietary polyunsaturated fatty acids on neuronal function. Lipids 1999 Feb; 34(2): 161–9PubMedCrossRef
65.
Goustard-Langelier B, Guesnet P, Durand G, et al. n-3 and n-6 fatty acid enrichment by dietary fish oil and phospholipid sources in brain cortical areas and nonneural tissues of formula-fed piglets. Lipids 1999; 34(1): 5–16PubMedCrossRef
66.
Youdim KA, Martin A, Joseph J. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 2000 Jul–Aug; 18(4–5): 383–99PubMedCrossRef
67.
Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res 1999 Jun 15; 56(6): 565–70PubMedCrossRef
68.
Rapoport SI, Chang MC, Spector AA. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res 2001 May; 42(5): 678–85PubMed
69.
Spector AA. Plasma free fatty acid and lipoproteins as sources of polyunsaturated fatty acid for the brain. J Mol Neurosci 2001 Apr–Jun; 16(2–3): 159–65PubMedCrossRef
70.
Jolivalt C, Leininger-Muller B, Bertrand P, et al. Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Radic Biol Med 2000 Jan 1; 28(1): 129–40PubMedCrossRef
71.
Smith JD, Miyata M, Poulin SE, et al. The relationship between apolipoprotein E and serum oxidation-related variables is apolipoprotein E phenotype dependent. Int J Clin Lab Res 1998; 28(2): 116–21PubMedCrossRef
72.
Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996 Sep; 14(1): 55–61PubMedCrossRef
73.
Kashiwagi S, Nakamura K, Arai H, et al. Electrophoretic analysis of oxidative modification of apolipoprotein E in very low density lipoprotein from fresh human plasma. Electrophoresis 1999 Jun; 20(7): 1418–24PubMedCrossRef
74.
Bassett CN, Montine KS, Neely MD, et al. Cerebrospinal fluid lipoproteins in Alzheimer’s disease. Microsc Res Tech 2000 Aug 15; 50(4): 282–6PubMedCrossRef
75.
Tamaoka A, Miyatake F, Matsuno S, et al. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer’s disease. Neurology 2000 Jun 27; 54(12): 2319–21PubMedCrossRef
76.
Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci 2001 May 1; 21(9): 3017–23PubMed
77.
Baloyannis S. Oxidative stress and mitochondria alterations in Alzheimer’s disease. [poster no. 1209]. 7th International Conference on Alzheimer’s Disease and Related Disorders; 2000 Jul 9–18; Washington, DC. Neurobiol Aging 2000 May–Jun: 21(1S): S264CrossRef
78.
Baloyannis S, Manolidis SL, Manolidis LS. Synaptic alterations in the vestibulocerebellar system in Alzheimer’s disease: a Golgi and electron microscope study. Acta Otolaryngol 2000 Mar; 120(2): 247–50PubMedCrossRef
79.
Terry RD. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 1996 Oct; 55(10): 1023–5PubMed
80.
Bi X, Zhou J, Lynch G. Lysosomal protease inhibitors induce meganeurites and tangle-like structures in entorhinohippo-campal regions vulnerable to Alzheimer’s disease. Exp Neurol 1999 Aug; 158(2): 312–27PubMedCrossRef
81.
Ditaranto K, Tekirian TL, Yang AJ. Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer’s disease. Neurobiol Dis 2001 Feb; 8(1): 19–31PubMedCrossRef
82.
Cataldo AM, Hamilton DJ, Barnett JL, et al. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer’s disease. J Neurosci 1996 Jan; 16(1): 186–99PubMed
83.
Pettegrew JW, Klunk WE, Kanal E, et al. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol Aging 1995 Nov–Dec; 16(6): 973–5PubMedCrossRef
84.
Sastre J, Pallardo FV, Vina J. Mitochondrial oxidative stress plays a key role in aging and apoptosis. IUBMB Life 2000 May; 49(5): 427–35PubMedCrossRef
85.
Cataldo AM, Hamilton DJ, Nixon RA. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res 1994 Mar 21; 640(1–2): 68–80PubMedCrossRef
86.
Lauderback CM, Kanski J, Hackett JM, et al. Apolipoprotein E modulates Alzheimer’s Abeta (l–42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res 2002 Jan 4; 924(1): 90–7PubMedCrossRef
87.
Brenner C, Kroemer G. Mitochondria — the death signal integrators. Science 2000 Aug 18; 289: 1150–1PubMedCrossRef
88.
Graves AB, Rajaram L, Bowen JD, et al. Cognitive decline and Japanese culture in a cohort of older Japanese Americans in King County, WA: the Kame Project. J Gerontol B Psychol Sci Soc Sci 1999 May; 54(3): S154–61PubMedCrossRef
89.
Solfrizzi V, Panza F, Torres F, et al. High monounsaturated fatty acids intake protects against age-related cognitive decline. Neurology 1999 May 12; 52(8): 1563–9PubMedCrossRef
90.
Otsuka M, Yamaguchi K, Ueki A. Similarities and differences between Alzheimer’s disease and vascular dementia from the viewpoint of nutrition. Ann N Y Acad Sci 2002; 977: 155–61PubMedCrossRef
91.
Braak H, Braak E, Bohl J, et al. Evolution of Alzheimer’s disease related cortical lesions. J Neural Transm Suppl 1998; 54: 97–106PubMed
92.
Cotman CW, Nieto-Sampedro M, Harris EW. Synapse replacement in the nervous system of adult vertebrates. Physiol Rev 1981; 61: 684–784PubMed
93.
Poirier J, Baccichet A, Dea D, et al. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 1993 Jul; 55(1): 81–90PubMedCrossRef
94.
Steward O. Lesion-induced synapse reorganization in the hippocampus of cats: sprouting of entorhinal, commissural/associational, and mossy fiber projections after unilateral entorhinal cortex lesions, with comments on the normal organization of these pathways. Hippocampus 1992 Jul; 2(3): 247–68PubMedCrossRef
95.
Geddes JW, Wilson MC, Miller FD, et al. Molecular markers of reactive plasticity. Adv Exp Med Biol 1990; 268: 425–32PubMed
96.
Nishino H, Hida H, Kumazaki M, et al. The striatum is the most vulnerable region in the brain to mitochondrial energy compromise: a hypothesis to explain its specific vulnerability. J Neurotrauma 2000 Mar; 17(3): 251–60PubMedCrossRef
97.
Blass JP. The mitochondrial spiral: an adequate cause of dementia in the Alzheimer’s syndrome. Ann N Y Acad Sci 2000; 924: 170–83PubMedCrossRef
98.
Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer’s disease. J Neurochem 1998 Nov; 71(5): 2034–40PubMedCrossRef
99.
Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol 1994 Nov; 36(5): 747–51PubMedCrossRef
100.
Nunomura A, Perry G, Pappolla MA, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer’s disease. J Neurosci 1999 Mar 15; 19(6): 1959–64PubMed
101.
de la Monte SM, Luong T, Neely TR, et al. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer’s disease. Lab Invest 2000 Aug; 80(8): 1323–35PubMedCrossRef
102.
Gamblin TC, King ME, Kuret J, et al. Oxidative regulation of fatty acid-induced tau polymerization. Biochemistry 2000 Nov 21; 39(46): 14203–10PubMedCrossRef
103.
Pettegrew JW, Panchalingam K, Klunk WE, et al. Alterations of cerebral metabolism in probable Alzheimer’s disease: a preliminary study. Neurobiol Aging 1994 Jan–Feb; 15(1): 117–32PubMedCrossRef
104.
Montine TJ, Markesbery WR, Zackert W, et al. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not the density of neuritic plaques or neurofibrillary tangles or with APOE Genotype in Alzheimer’s disease patients. Am J Pathol 1999; 155: 863–8PubMedCrossRef
105.
Miatto O, Gonzalez RG, Buonanno F, et al. In vitro 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer’s disease. Can J Neurol Sci 1986 Nov; 13(4 Suppl.): 535–9PubMed
106.
Cuenod CA, Kaplan DB, Michot JL, et al. Phospholipid abnormalities in early Alzheimer’s disease: in vivo phosphorus 31 magnetic resonance spectroscopy. Arch Neurol 1995 Jan; 52(1): 89–94PubMedCrossRef
107.
Pettegrew JW, Klunk WE, Panchalingam K, et al. Magnetic resonance spectroscopic changes in Alzheimer’s disease. Ann N Y Acad Sci 1997 Sep 26; 826: 282–306PubMedCrossRef
108.
Yanagisawa K, McLaurin J, Michikawa M, et al. Amyloid beta-protein (A beta) associated with lipid molecules: immunoreactivity distinct from that of soluble A beta. FEBS Lett 1997 Dec 22; 420(1): 43–6PubMedCrossRef
109.
Yanagisawa K, Asami-Odaka A, Suzuki N, et al. Fractionation of amyloid beta-protein (A beta) in Alzheimer’s disease and Down’s syndrome brains: presence of membrane-bound A beta. Ann N Y Acad Sci 1996 Jun 15; 786: 184–94PubMedCrossRef
110.
Yamaguchi H, Maat-Schieman ML, van Duinen SG, et al. Amyloid beta protein (Abeta) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects. J Neuropathol Exp Neurol 2000 Aug; 59(8): 723–32PubMed
111.
Buchet R, Pikula S. Alzheimer’s disease: its origin at the membrane, evidence and questions. Acta Biochim Pol 2000; 47(3): 725–33PubMed
112.
Waschuk SA, Elton EA, Darabie AA, et al. Cellular membrane composition defines A beta-lipid interactions. J Biol Chem 2001 Sep 7; 276(36): 33561–8PubMedCrossRef
113.
Koppaka V, Axelsen PH. Accelerated accumulation of amyloid beta proteins on oxidatively damaged lipid membranes. Biochemistry 2000 Aug 15; 39(32): 10011–6PubMedCrossRef
114.
Butterfield DA, Drake J, Pocernich C, et al. Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001 Dec; 7(12): 548–54PubMedCrossRef
115.
Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress (1,2). Free Radic Biol Med 2002 Jun 1; 32(11): 1050–60PubMedCrossRef
116.
Varadarajan S, Kanski J, Aksenova M, et al. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer’s A beta (1–42) and A beta (25–35). J Am Chem Soc 2001 Jun 20; 123(24): 5625–31PubMedCrossRef
117.
Smith MA, Rottkamp CA, Nunomura A, et al. Oxidative stress in Alzheimer’s disease. Biochim Biophys Acta 2000 Jul 26; 1502(1): 139–44PubMedCrossRef
118.
Schippling S, Kontush A, Arlt S, et al. Increased lipoprotein oxidation in Alzheimer’s disease. Free Radic Biol Med 2000 Feb 1; 28(3): 351–60PubMedCrossRef
119.
Berthon G. Does human betaA4 exert a protective function against oxidative stress in Alzheimer’s disease? Med Hypotheses 2000 Apr; 54(4): 672–7PubMedCrossRef
120.
Kontush A. Alzheimer’s amyloid-beta as a preventive antioxidant for brain lipoproteins. Cell Mol Neurobiol 2001 Aug; 21(4): 299–315PubMedCrossRef
121.
Kontush A. Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer’s disease. Free Radic Biol Med 2001 Nov 1; 31(9): 1120–31PubMedCrossRef
122.
Kontush A, Berndt C, Weber W, et al. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 2001 Jan 1; 30(1): 119–28PubMedCrossRef
123.
Zou K, Gong JS, Yanagisawa K, et al. A novel function of monomelic amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 2002 Jun 15; 22(12): 4833–41PubMed
124.
Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001 Aug; 60(8): 759–67PubMed
125.
Pratico D, Clark CM, Lee VM, et al. Increased 8,12-iso-iPF2alpha-VI in Alzheimer’s disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000 Nov; 48(5): 809–12PubMedCrossRef
126.
Masliah E. Recent advances in the understanding of the role of synaptic proteins in Alzheimer’s Disease and other neurodegenerative disorders. J Alzheimers Dis 2001 Feb; 3(1): 121–9PubMed
127.
Lovestone S, McLoughlin DM. Protein aggregates and dementia: is there a common toxicity? J Neurol Neurosurg Psychiatry 2002 Feb; 72(2): 152–61PubMedCrossRef
128.
Emmerling MR, Moore CJ, Doyle PD, et al. Phospholipase A2 activation influences the processing and secretion of the amyloid precursor protein. Biochem Biophys Res Commun 1993 Nov 30; 197(1): 292–7PubMedCrossRef
129.
Emmerling MR, Dudley DT, Dyer RD, et al. The role of arachidonic acid in the secretion of the amyloid precursor protein (APP). Ann N Y Acad Sci 1996 Jan 17; 777: 310–5PubMedCrossRef
130.
Lehtonen JY, Holopainen JM, Kinnunen PK. Activation of phospholipase A2 by amyloid beta-peptides in vitro. Biochemistry 1996 Jul 23; 35(29): 9407–14PubMedCrossRef
131.
Stephenson DT, Lemere CA, Selkoe DJ, et al. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer’s disease brain. Neurobiol Dis 1996 Feb; 3(1): 51–63PubMedCrossRef
132.
Gattaz WF, Maras A, Cairns NJ, et al. Decreased phospholipase A2 activity in Alzheimer brains. Biol Psychiatry 1995 Jan 1; 37(1): 13–7PubMedCrossRef
133.
Guan ZZ, Zhang X, Mousavi M, et al. Reduced expression of neuronal nicotinic acetylcholine receptors during the early stages of damage by oxidative stress in PC12 cells. J Neurosci Res 2001 Nov 15; 66(4): 551–8PubMedCrossRef
134.
Nitsch RM, Blusztajn JK, Pittas AG, et al. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 1992 Mar 1; 89(5): 1671–5PubMedCrossRef
135.
Farooqui AA, Wells K, Horrocks LA. Breakdown of membrane phospholipids in Alzheimer disease: involvement of excitatory amino acid receptors. Mol Chem Neuropathol 1995 Jun–Aug; 25(2–3): 155–73PubMedCrossRef
136.
Mayes PA. Metabolism of unsaturated fatty acids and eicosanoids. In: Murray RK, Granner DK, Mayes PA, et al. Harper’s biochemistry. 25th ed. Stamford (CT): McGraw-Hill, 1999: 250–8
137.
Hubbell WL, McConnell HM. Molecular motion in spin-labeled phospholipids and membranes. J Am Chem Soc 1971 Jan 27; 93(2): 314–26PubMedCrossRef
138.
Jost P, Libertini LJ, Hebert VC, et al. Lipid spin labels in lecithin multilayers: a study of motion along fatty acid chains. J Mol Biol 1971 Jul 14; 59(1): 77–98PubMedCrossRef
139.
Chen L, Johnson ML, Biltonen RL. A macroscopic description of lipid bilayer phase transitions of mixed-chain phosphatidylcholines: chain-length and chain-asymmetry dependence. Biophys J 2001 Jan; 80(1): 254–70PubMedCrossRef
140.
Fischer S. Dietary polyunsaturated fatty acids and eicosanoid formation in humans. Adv Lipid Res 1989; 23: 169–98PubMed
141.
Smith WL, Fitzpatrick FA. The eicosanoids: cyclooxygenase, lipozygenase, and epoxygenase pathways. In: Vance DE, Vance JE, editors. Biochemistry of lipids, lipoproteins and membranes. Amsterdam: Elsevier, 1996
142.
Brown MS, Goldstein JL. The LDL receptor and HMG-CoA reductase: two membrane molecules that regulate cholesterol homeostasis. Curr Top Cell Regul 1985; 26: 3–15PubMed
143.
Bjorkhem I, Andersson U, Ellis E, et al. From brain to bile: evidence that conjugation and omega-hydroxylation are important for elimination of 24S-hydroxycholesterol (cerebrosterol) in humans. J Biol Chem 2001 Oct 5; 276(40): 37004–10PubMedCrossRef
144.
Demeester N, Castro G, Desrumaux C, et al. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer’s disease. J Lipid Res 2000 Jun; 41(6): 963–74PubMed
145.
Koudinov AR, Koudinova NV, Kumar A, et al. Biochemical characterization of Alzheimer’s soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun 1996 Jun 25; 223(3): 592–7PubMedCrossRef
146.
Guyton JR, Miller SE, Martin ME, et al. Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid. J Neurochem 1998 Mar; 70(3): 1235–40PubMedCrossRef
147.
Carlsson J, Armstrong VW, Reiber H, et al. Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chim Acta 1991 Feb 15; 196(2–3): 167–76PubMedCrossRef
148.
Rebeck GW, Alonzo NC, Berezovska O, et al. Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. Exp Neurol 1998 Jan; 149(1): 175–82PubMedCrossRef
149.
Edmond J, Higa TA, Korsak RA, et al. Fatty acid transport and utilization for the developing brain. J Neurochem 1998 Mar; 70(3): 1227–34PubMedCrossRef
150.
Dehouck B, Fenart L, Dehouck MP, et al. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 1997 Aug 25; 138(4): 877–89PubMedCrossRef
151.
Danik M, Champagne D, Petit-Turcotte C, et al. Brain lipoprotein metabolism and its relation to neurodegenerative disease. Crit Rev Neurobiol 1999; 13(4): 357–407PubMed
152.
Qi K, Hall M, Deckelbaum RJ. Long-chain polyunsaturated fatty acid accretion in brain. Curr Opin Clin Nutr Metab Care 2002 Mar; 5(2): 133–8PubMedCrossRef
153.
Reaven P, Parthasarathy S, Grasse BJ, et al. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholester-olemic subjects. J Clin Invest 1993 Feb; 91(2): 668–76PubMedCrossRef
154.
Holman RT, Elmer OC. The rates of oxidation of unsaturated fatty acids and esters. J Am Oil Chem Soc 1947; 24: 127–9CrossRef
155.
Cosgrove JP, Church DF, Pryor WP. The kinetics of the autoxidation of polyunsaturated fatty acids. Lipids 1987; 22: 299–304PubMedCrossRef
156.
Harats D, Dabach Y, Hollander G, et al. Fish oil ingestion in smokers and nonsmokers enhances peroxidation of plasma lipoproteins. Atherosclerosis 1991 Oct; 90(2–3): 127–39PubMedCrossRef
157.
Hornstra G, Oostenbrug GS, Vossen RC. Peroxidation of low density lipoproteins and endothelial phospholipids: effect of vitamin E and fatty acid composition. World Rev Nutr Diet 1994; 75: 149–54PubMed
158.
Turini ME, Crozier GL, Donnet-Hughes A, et al. Short-term fish oil supplementation improved innate immunity, but increased ex vivo oxidation of LDL in man: a pilot study. Eur J Nutr 2001 Apr; 40(2): 56–65PubMedCrossRef
159.
Yamamoto N, Okaniwa Y, Mori S, et al. Effects of a high-linoleate and a high-alpha-linolenate diet on the learning ability of aged rats: evidence against an autoxidation-related lipid peroxide theory of aging. J Gerontol 1991 Jan; 46(1): B17–22PubMedCrossRef
160.
Higdon JV, Liu J, Du SH, et al. Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F (2)-isoprostanes. Am J Clin Nutr 2000 Sep; 72(3): 714–22PubMed
161.
Turpeinen AM, Alfthan G, Valsta L, et al. Plasma and lipoprotein lipid peroxidation in humans on sunflower and rapeseed oil diets. Lipids 1995 Jun; 30(6): 485–92PubMedCrossRef
162.
Higdon JV, Du SH, Lee YS, et al. Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate. J Lipid Res 2001 Mar; 42(3): 407–18PubMed
163.
de Ruiz GJ, Mertxe de Renobales, del Cerro A, et al. Habitual fish intake is associated with decreased LDL susceptibility to ex vivo oxidation. Lipids 2002 Apr; 37(4): 333–41PubMedCrossRef
164.
Wander RC, Du SH, Thomas DR. Influence of long-chain polyunsaturated fatty acids on oxidation of low density lipoprotein. Prostaglandins Leukot Essent Fatty Acids 1998 Aug; 59(2): 143–51PubMedCrossRef
165.
Kleinveld HA, Naber AH, Stalenhoef AF, et al. Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in vitamin E deficient subjects. Free Radic Biol Med 1993 Sep; 15(3): 273–80PubMedCrossRef
166.
Parthasarathy S, Khoo JC, Miller E, et al. Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci U S A 1990 May; 87(10): 3894–8PubMedCrossRef
167.
Hargrove RL, Etherton TD, Pearson TA, et al. Low fat and high monounsaturated fat diets decrease human low density lipoprotein oxidative susceptibility in vitro. J Nutr 2001 Jun; 131(6): 1758–63PubMed
168.
Kratz M, Cullen P, Kannenberg F, et al. Effects of dietary fatty acids on the composition and oxidizability of low-density lipoprotein. Eur J Clin Nutr 2002 Jan; 56(1): 72–81PubMedCrossRef
169.
Wander RC, Du SH. Oxidation of plasma proteins is not increased after supplementation with eicosapentaenoic and docosahexaenoic acids. Am J Clin Nutr 2000 Sep; 72(3): 731–7PubMed
170.
Kubo K, Saito M, Tadokoro T, et al. Dietary docosahexaenoic acid dose not promote lipid peroxidation in rat tissue to the extent expected from peroxidizability index of the lipids. Biosci Biotechnol Biochem 1998 Sep; 62(9): 1698–706PubMedCrossRef
171.
Yavin E, Brand A, Green P. Docosahexaenoic acid abundance in the brain: a biodevice to combat oxidative stress. Nutr Neurosci 2002 Jun; 5(3): 149–57PubMedCrossRef
172.
Kalmijn S, Launer LJ, Ott A, et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997; 42(5): 776–82PubMedCrossRef
173.
Kalmijn S, Feskiens EJ, Launer LJ, et al. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 1997; 145(1): 33–41PubMedCrossRef
174.
Kalmijn S. Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J Nutr Health Aging 2000; 4(4): 202–7PubMed
175.
Morris MC, Evans DA, Bienias JL, et al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 2003; 60(2): 194–200PubMedCrossRef
176.
Berliner JA, Subbanagounder G, Leitinger N, et al. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001 Apr–May; 11(3–4): 142–7PubMedCrossRef
177.
Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989 Apr 6; 320(14): 915–24PubMedCrossRef
178.
Kremer JJ, Sklansky DJ, Murphy R. Profile of changes in lipid bilayer structure caused by beta-amyloid peptide. Biochemistry 2001; 40: 8563–71PubMedCrossRef
179.
Borst JW, Visser NV, Kouptsova O, et al. Oxidation of unsaturated phopholipids in membrane bilayer mixtures is accompanied by membrane fluidity changes. Biochem Biophys Acta 2000 Aug 24; 1487(1): 61–73PubMedCrossRef
180.
Prasad MR, Lovell MA, Yatin M, et al. Regional membrane phospholipid alterations in Alzheimer’s disease. Neurochem Res 1998; 23(1): 81–8PubMedCrossRef
181.
Wells K, Farooqui AA, Liss L, et al. Neural membrane phospholipids in Alzheimer’s disease. Neurochem Res 1995; 20: 1329–33PubMedCrossRef
182.
Corrigan FM, Horrobin DF, Skinner ER, et al. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer’s disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol 1998 Feb; 30(2): 197–207PubMedCrossRef
183.
Zubenko GS. Hippocampal membrane alteration in Alzheimer’s disease. Brain Research 1986; 385: 115–21PubMedCrossRef
184.
Bertoni-Freddari C, Fattoretti P, Casoli T, et al. Structural dynamics of synaptic junctional areas in aging and Alzheimer’s disease. Ann N Y Acad Sci 1992 Dec 26; 673: 285–92PubMedCrossRef
185.
Roth GS, Joseph JA, Mason RP. Membrane alterations as causes of impaired signal transduction in Alzheimer’s disease and aging. Trends Neurosci 1995; 18: 203–6PubMedCrossRef
186.
Subramaniam R, Roediger F, Jordan B, et al. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem 1997 Sep; 69(3): 1161–9PubMedCrossRef
187.
Mattson MP, Fu W, Waeg G, et al. 4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. Neuroreport 1997 Jul 7; 8(9–10): 2275–81PubMedCrossRef
188.
Pedersen WA, Chan SL, Mattson MP. A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxy-nonenal. J Neurochem 2000 Apr; 74(4): 1426–33PubMedCrossRef
189.
Sparks DL. Intraneuronal beta-amyloid immunoreactivity in the CNS. Neurobiol Aging 1996 Mar–Apr; 17(2): 291–9PubMedCrossRef
190.
Yang AJ, Chandswangbhuvana D, Shu T, et al. Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abetal-42. J Biol Chem 1999 Jul 16; 274(29): 20650–6PubMedCrossRef
191.
Walsh DM, Tseng BP, Rydel RE, et al. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000 Sep 5; 39(35): 10831–9PubMedCrossRef
192.
Gouras GK, Tsai J, Naslund J, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 2000 Jan; 156(1): 15–20PubMedCrossRef
193.
Yang AJ, Chandswangbhuvana D, Margol L, et al. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abetal-42 pathogenesis. J Neurosci Res 1998 Jun 15; 52(6): 691–8PubMedCrossRef
194.
Mecocci P, Beal MF, Cecchetti R, et al. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 1997; 31: 53–64PubMedCrossRef
195.
Nagy Z, Esiri MM, LeGris M, et al. Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathol (Berl) 1999 Apr; 97(4): 346–54CrossRef
196.
Ebneth A, Godemann R, Stamer K, et al. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer’s disease. J Cell Biol 1998 Nov 2; 143(3): 777–94PubMedCrossRef
197.
de la Monte SM, Wands JR. Alzheimer-associated neuronal thread protein-induced apoptosis and impaired mitochondrial function in human central nervous system-derived neuronal cells. J Neuropathol Exp Neurol 2001 Feb; 60(2): 195–207PubMed
198.
Smith MA, Drew KL, Nunomura A, et al. Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? Neurochem Int 2002 May; 40(6): 527–31PubMedCrossRef
199.
Mitchell TW, Mufson EJ, Schneider JA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer’s disease. Ann Neurol 2002 Feb; 51(2): 182–9PubMedCrossRef
200.
Mayes PA. Lipids of physiological significance. In: Murray RK, Granner DK, Mayes PA, et al., editors. Harper’s biochemistry. Norwalk (CT): Appleton & Lange, 1996: 160–172
201.
Porter NA, Caldwell SE, Mills KA. Mechanisms of free radical oxidation of unsaturated lipids. Lipids 1995 Apr; 30(4): 277–90PubMedCrossRef
202.
Lorenz R, Spengler U, Fischer S, et al. Platelet function, thromboxane formation and blood pressure control during supplementation of the Western diet with cod liver oil. Circulation 1983 Mar; 67(3): 504–11PubMedCrossRef
203.
Mark RJ, Pang Z, Geddes JW, et al. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 1997 Feb 1; 17(3): 1046–54PubMed
204.
Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer’s disease due to an IL-l-/IL-6-mediated ‘acute phase response’ in the brain? Immunol Today 1991; 12: 7–219CrossRef
205.
Ramassamy C, Averill D, Beffert U, et al. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer’s disease brain. Neurobiol Dis 2000 Feb; 7(1): 23–37PubMedCrossRef
206.
Ramassamy C, Krzywkowski P, Averill D, et al. Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain. Brain Res Mol Brain Res 2001 Jan 31; 86(1–2): 76–83PubMedCrossRef
207.
Lesser G, Kandiah K, Libow LS, et al. Elevated serum total and LDL cholesterol in very old patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2001 Mar–Apr; 12(2): 138–45PubMedCrossRef
208.
Svennerholm L, Gottfries CG. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 1994 Mar; 62(3): 1039–47PubMedCrossRef
209.
Gottfries CG, Karlsson I, Svennerholm L. Membrane components separate early-onset Alzheimer’s disease from senile dementia of the Alzheimer type. Int Psychogeriatr 1996 Fall; 8(3): 365–72PubMedCrossRef
210.
Yoshida S, Yasuda A, Kawazato H, et al. Synaptic vesicle ultrastructural changes in the rat hippocampus induced by a combination of alpha-linolenate deficiency and a learning task. J Neurochem 1997 Mar; 68(3): 1261–8PubMedCrossRef
211.
Masliah E, Mallory M, Hansen L, et al. Synaptic and neuritic alterations during the progression of Alzheimer’s disease. Neurosci Lett 1994 Jun 6; 174(1): 67–72PubMedCrossRef
212.
Svennerholm L, Bostrom K, Helander CG, et al. Membrane lipids in the aging human brain. J Neurochem 1991 Jun; 56(6): 2051–9PubMedCrossRef
213.
Skinner ER, Watt C, Besson JA, et al. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer’s disease and control subjects. Brain 1993 Jun; 116 (Pt 3): 717–25PubMedCrossRef
214.
Spiteller G. Are changes of the cell membrane structure causally involved in the aging process? Ann N Y Acad Sci 2002 Apr; 959: 30–44PubMedCrossRef
215.
Barberger-Gateau P, Letenneur L, Deschamps V, et al. Fish, meat, and risk of dementia: cohort study. BMJ 2002; 325: 932–3PubMedCrossRef
216.
Meydani M, Meydani M. Nutrition interventions in aging and age-associated disease. Proc Nutr Soc 2002 May; 61(2): 165–71PubMedCrossRef
217.
Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997 Apr 24; 336(17): 1216–22PubMedCrossRef
218.
Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002; 287(24): 3230–7PubMedCrossRef
219.
Laurin D, Verreault R, Lindsay J, et al. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001 Mar; 58(3): 498–504PubMedCrossRef
220.
Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke ina multiethnic cohort. Am J Epidemiol 2001; 154(7): 635–41PubMedCrossRef
221.
Peila R, Rodriguez BL, Launer LJ. Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002 Apr; 51(4): 1256–62PubMedCrossRef
222.
Hall KS, Gao S, Unverzagt FW, et al. Low education and childhood rural residence: risk for Alzheimer’s disease in African Americans. Neurology 2000 Jan 11; 54(1): 95–9PubMedCrossRef
223.
Moceri VM, Kukull WA, Emanuel I, et al. Early-life risk factors and the development of Alzheimer’s disease. Neurology 2000 Jan 25; 54(2): 415–20PubMedCrossRef
224.
Johnson RK, Guthrie H, Smiciklas-Wright H, et al. Characterizing nutrient intakes of children by sociodemographic factors. Public Health Rep 1994 May–Jun; 109(3): 414–20PubMed
225.
Dobson A, Mishra G, Brown W, et al. Food habits of young and middle-aged women living outside the capital cities of Australia. Aust N Z J Public Health 1997 Dec; 21(7): 711–5PubMedCrossRef
226.
Fidanza F, Fidanza AA, Coli R, et al. Food and nutrient consumption of two rural Italian population groups followed for twenty years. Int J Vitam Nutr Res 1984; 54(1): 91–7PubMed
227.
Liang H, Ozasa K, Higashi A, et al. Comparison of a rural town and a fishing town: diet and circulatory system diseases. Nippon Eiseigaku Zasshi 1993 Oct; 48(4): 830–7PubMedCrossRef
228.
Schuck C, Tartt JB. Food consumption of low-income, rural Negro households in Mississippi. J Am Diet Assoc 1973 Feb; 62(2): 151–5PubMed
229.
Leino M, Raitakari OT, Porkka KV, et al. Cardiovascular risk factors of young adults in relation to parental socioeconomic status: the Cardiovascular Risk in Young Finns Study. Ann Med 2000 Mar; 32(2): 142–51PubMedCrossRef
230.
Galobardes B, Morabia A, Bernstein MS. Diet and socioeconomic position: does the use of different indicators matter? Int J Epidemiol 2001 Apr; 30(2): 334–40PubMedCrossRef
231.
Sheshadri S, Drachman DA, Lippa CF. Apolipoprotein E4 allele and the lifetime risk of Alzheimer’s disease: what physicians know, and what they should know. Arch Neurology 1995; 52: 1074–9CrossRef
232.
Eckert GP, Cairns NJ, Maras A, et al. Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer’s disease. Dement Geriatr Cogn Disord 2000 Jul–Aug; 11(4): 181–6PubMedCrossRef
233.
Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998 May 26; 95(11): 6460–4PubMedCrossRef
234.
Frears ER, Stephens DJ, Walters CE, et al. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 1999 Jun 3; 10(8): 1699–705PubMedCrossRef
235.
von Schacky C, Fischer S, Weber PC. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest 1985 Oct; 76(4): 1626–31CrossRef
236.
Reaven P, Parthasarathy S, Grasse BJ, et al. Feasibility of using an oleate-rich diet to reduce the susceptibility of low-density lipoprotein to oxidative modification in humans. Am J Clin Nutr 1991 Oct; 54(4): 701–6PubMed
237.
Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000 Nov; 356: 1627–31PubMedCrossRef
238.
Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002 Feb; 59: 223–7PubMedCrossRef
239.
Wolozin B, Kellman W, Rousseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57(10): 1439–43PubMedCrossRef
240.
Locatelli S, Lutjohann D, Schmidt H H-J, et al. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 2002 Feb; 59: 213–6PubMedCrossRef
241.
Kleinveld HA, Demacker PN, De Haan AF, et al. Decreased in vitro oxidizability of low-density lipoprotein in hypercholes-terolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest 1993 May; 23(5): 289–95PubMedCrossRef
242.
Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999; 10: 543–59PubMedCrossRef
243.
Tanaka K, Yasuhara M, Suzumura K, et al. Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages. Jpn J Pharmacol 2001 Jul; 86(3): 289–96PubMedCrossRef
244.
Orem C, Orem A, Uydu HA, et al. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coron Artery Dis 2002 Feb; 13(1): 65–71PubMedCrossRef
245.
Cofan F, Zambon D, Laguna JC, et al. Pravastatin improves low-density lipoprotein oxidation in renal transplantation. Transplant Proc 2002 Feb; 34(1): 389–91PubMedCrossRef
246.
Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998 Sep 1; 98(9): 839–44PubMedCrossRef
247.
Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999 Jan 9; 353(9147): 118–9PubMedCrossRef
248.
Endres M, Laufs U, Huang ZH, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998 Jul 21; 95(15): 8880–5PubMedCrossRef
249.
Kaesemeyer WH, Caldwell RB, Huang J, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999 Jan; 33(1): 234–41PubMedCrossRef
250.
Kojro E, Gimpl G, Lammich S, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A 2001 May 8; 98(10): 5815–20PubMedCrossRef
251.
Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology 1998; 17(1): 14–20PubMedCrossRef
252.
Mulder M, Ravid R, Swaab DF, et al. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis Assoc Disord 1998 Sept; 12(3): 198–203PubMedCrossRef
253.
Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2002 Jul–Sep; 16(3): 131–6PubMedCrossRef
254.
Das UN. Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essent Fatty Acids 2001 Jul; 65(1): 37–40PubMedCrossRef
255.
Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002 Sep; 52(3): 346–50PubMedCrossRef
256.
Petanceska SS, DeRosa S, Olm V, et al. Statin therapy for Alzheimer’s disease: will it work?. J Mol Neurosci 2002 Aug–Oct; 19(1–2): 155–61PubMedCrossRef
257.
Sparks DL, Martin TA, Gross DR, et al. Link between heart disease, cholesterol, and Alzheimer’s disease: a review. Microsc Res Tech 2000 Aug 15; 50(4): 287–90PubMedCrossRef
258.
Sparks DL, Connor DJ, Browne PJ, et al. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer’s disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging 2002; 6(5): 324–31PubMed
Metadata
Title
Dietary Lipids in the Aetiology of Alzheimer’s Disease
Implications for Therapy
Author
Dr Janelle L. Cooper
Publication date
01-05-2003
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 6/2003
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200320060-00001

Other articles of this Issue 6/2003

Drugs & Aging 6/2003 Go to the issue

Guest Commentary

Memantine

Review Article

Drug Interactions with Cholinesterase Inhibitors

Therapy in Practice

Prevention and Treatment of Diabetic Nephropathy in Older Patients

Review Article

Cardiovascular Drug Therapy in the Elderly: Theoretical and Practical Considerations

Guest Commentary

Memantine

Adis Drug Profile

Memantine
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits